Published on 15 May 2023 on Simply Wall St. via Yahoo Finance
These Analysts Think Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) Sales Are Under Threat
The analysts covering Inovio Pharmaceuticals, Inc. (NASDAQ:INO) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
Following the latest downgrade, the current consensus, from the four analysts covering Inovio Pharmaceuticals, is for revenues of US$920k in 2023, which would reflect a painful 91% reduction in Inovio Pharmaceuticals' sales over the past 12 months. Losses are predicted to fall substantially, shrinking 37% to US$0.58. However, before this estimates update, the consensus had been expecting revenues of US$1.1m and US$0.53 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.
See our latest analysis for Inovio Pharmaceuticals